Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. (2023)

First Author: Jenkin D
Attributed to:  Pathogen Genomics, Phenotype and Immunity (PGPI) & Basic Sciences Programme funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(23)00068-3

PubMed Identifier: 37060917

Publication URI: http://europepmc.org/abstract/MED/37060917

Type: Journal Article/Review

Volume: 23

Parent Publication: The Lancet. Infectious diseases

Issue: 8

ISSN: 1473-3099